Protalix BioTherapeutics Inc (PLX)
1.14
-0.03
(-2.56%)
USD |
NYAM |
May 17, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Enterprise Value: 55.51M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 55.51M |
| May 16, 2024 | 57.71M |
| May 15, 2024 | 54.78M |
| May 14, 2024 | 56.98M |
| May 13, 2024 | 55.51M |
| May 10, 2024 | 52.58M |
| May 09, 2024 | 63.58M |
| May 08, 2024 | 55.51M |
| May 07, 2024 | 55.51M |
| May 06, 2024 | 53.31M |
| May 03, 2024 | 55.51M |
| May 02, 2024 | 56.98M |
| May 01, 2024 | 60.65M |
| April 30, 2024 | 55.51M |
| April 29, 2024 | 59.91M |
| April 26, 2024 | 55.94M |
| April 25, 2024 | 58.13M |
| April 24, 2024 | 60.33M |
| April 23, 2024 | 59.60M |
| April 22, 2024 | 58.13M |
| April 19, 2024 | 55.94M |
| April 18, 2024 | 54.48M |
| April 17, 2024 | 55.94M |
| April 16, 2024 | 55.21M |
| April 15, 2024 | 55.21M |
| Date | Value |
|---|---|
| April 12, 2024 | 58.13M |
| April 11, 2024 | 61.06M |
| April 10, 2024 | 63.98M |
| April 09, 2024 | 68.36M |
| April 08, 2024 | 66.90M |
| April 05, 2024 | 57.40M |
| April 04, 2024 | 60.33M |
| April 03, 2024 | 62.52M |
| April 02, 2024 | 62.52M |
| April 01, 2024 | 63.25M |
| March 31, 2024 | 63.98M |
| March 28, 2024 | 67.74M |
| March 27, 2024 | 67.01M |
| March 26, 2024 | 64.81M |
| March 25, 2024 | 64.81M |
| March 22, 2024 | 68.47M |
| March 21, 2024 | 72.12M |
| March 20, 2024 | 73.58M |
| March 19, 2024 | 70.66M |
| March 18, 2024 | 68.47M |
| March 15, 2024 | 72.85M |
| March 14, 2024 | 75.77M |
| March 13, 2024 | 86.73M |
| March 12, 2024 | 80.16M |
| March 11, 2024 | 80.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.45M
Minimum
Dec 03 2021
274.11M
Maximum
Feb 24 2021
92.69M
Average
84.07M
Median
Enterprise Value Benchmarks
| Agenus Inc | 199.88M |
| InfuSystems Holdings Inc | 166.25M |
| AIM ImmunoTech Inc | 7.729M |
| Perspective Therapeutics Inc | 817.27M |
| Armata Pharmaceuticals Inc | 187.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.595M |
| Revenue (Quarterly) | 3.748M |
| Total Expenses (Quarterly) | 8.604M |
| EPS Diluted (Quarterly) | -0.06 |
| Gross Profit Margin (Quarterly) | 30.58% |
| Profit Margin (Quarterly) | -122.6% |
| Earnings Yield | 0.88% |
| Operating Earnings Yield | 8.66% |
| Normalized Earnings Yield | 0.8772 |